DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Tranxene (Clorazepate Dipotassium) - Indications and Dosage

 
 



INDICATIONS AND USAGE

TRANXENE is indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic.

TRANXENE tablets are indicated as adjunctive therapy in the management of partial seizures.

The effectiveness of TRANXENE tablets in long-term management of anxiety, that is, more than 4 months, has not been assessed by systematic clinical studies. Long-term studies in epileptic patients, however, have shown continued therapeutic activity. The physician should reassess periodically the usefulness of the drug for the individual patient.

TRANXENE tablets are indicated for the symptomatic relief of acute alcohol withdrawal.

DOSAGE AND ADMINISTRATION

For the symptomatic relief of anxiety:

TRANXENE T-TAB tablets are administered orally in divided doses. The usual daily dose is 30 mg. The dose should be adjusted gradually within the range of 15 to 60 mg daily in accordance with the response of the patient. In elderly or debilitated patients it is advisable to initiate treatment at a daily dose of 7.5 to 15 mg.

TRANXENE tablets may also be administered in a single dose daily at bedtime; the recommended initial dose is 15 mg. After the initial dose, the response of the patient may require adjustment of subsequent dosage. Lower doses may be indicated in the elderly patient. Drowsiness may occur at the initiation of treatment and with dosage increment.

For the symptomatic relief of acute alcohol withdrawal:

The following dosage schedule is recommended:

1st 24 hours (Day 1) 30 mg initially; followed by 30 to 60 mg in divided doses
2nd 24 hours (Day 2) 45 to 90 mg in divided doses
3rd 24 hours (Day 3) 22.5 to 45 mg in divided doses
Day 4 15 to 30 mg in divided doses

Thereafter, gradually reduce the daily dose to 7.5 to 15 mg. Discontinue drug therapy as soon as patient’s condition is stable.

The maximum recommended total daily dose is 90 mg. Avoid excessive reductions in the total amount of drug administered on successive days.

As an Adjunct to Antiepileptic Drugs:

In order to minimize drowsiness, the recommended initial dosages and dosage increments should not be exceeded.

Adults:

The maximum recommended initial dose in patients over 12 years old is 7.5 mg three times a day. Dosage should be increased by no more than 7.5 mg every week and should not exceed 90 mg/day.

Children (9-12 years):

The maximum recommended initial dose is 7.5 mg two times a day. Dosage should be increased by no more than 7.5 mg every week and should not exceed 60 mg/day.

HOW SUPPLIED

TRANXENE 3.75 mg scored T-TAB tablets are supplied as blue-colored tablets bearing the letters OV, the distinctive T shape and a two-digit designation, 31:

Bottles of 100 (NDC 55292-301-01).

7.5 mg scored T-TAB tablets are supplied as peach-colored tablets bearing the letters OV, the distinctive T shape and a two-digit designation, 32:

Bottles of 100 (NDC 55292-302-01).

15 mg scored T-TAB tablets are supplied as lavender-colored tablets bearing the letters OV, the distinctive T shape and a two-digit designation, 33:

Bottles of 100 (NDC 55292-303-01).

Recommended storage: Protect from moisture. Keep bottle tightly closed. Store at 20-25°C (68-77°F). See USP controlled room temperature. Dispense in a USP tight, light-resistant container.

T-TAB tablet appearance and shape are registered trademarks of Recordati Rare Diseases Inc.

U.S. Design Pat. No. D-300,879

Manufactured by: AbbVie LTD, Barceloneta, PR 00617

For: Recordati Rare Diseases Inc., Lebanon, NJ 08833, U.S.A.

RECORDATI RARE DISEASES GROUP

* Trademark of Sanofi-Aventis
® Trademark of Recordati Rare Diseases Inc.

Revised: February 2013

03-A771-R6

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017